Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ADAM metallopeptidase domain 20 pseudogene 3 (ADAM20P3) is classified as a pseudogene in the human genome, meaning it represents a DNA sequence closely related to the functional ADAM20 gene but is not itself capable of producing a functional protein product[1][3][4][5]. Pseudogenes are typically characterized by structural changes, such as premature stop codons, that disable their capacity for translation into active proteins[4][7]. ADAM20P3 is considered a close paralogue of ADAM20, part of the ADAM gene family, which encodes proteins generally involved in cell signaling, adhesion, and protease activity—but only when functional[4][6]. Because ADAM20P3 does not produce a functional protein, it is not considered a therapeutic target (i.e., not a receptor, enzyme, transporter, etc.), and there are no known drugs or disease associations relating to its activity[1][3][4][5]. The locus is located on chromosome 4: 188,667,248-188,669,353 on the reverse strand[3]. ADAM protein family pseudogenes like ADAM20P3 may be transcribed in certain tissues (notably testes), but lack protein-coding capacity and specific biological or disease functions[4][7]. Pseudogenes can sometimes have indirect roles, such as regulating related genes through non-coding RNA functions, but there is no reported evidence that ADAM20P3 has any such activity[1][3][4][5][7]. ADAM20P3 is a non-functional pseudogene of the ADAM family, with no biological activity, disease association, or drug interactions. It is not considered a therapeutic target, and its entry as a research target would be regarded as an error or misannotation.
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ADAM metallopeptidase domain 20 pseudogene 3 (ADAM20P3).